Clinical Trial Update: Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating plerixafor in combination with cemiplimab for metastatic pancreatic cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• Plerixafor (Plerixafor)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-02-20